Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Nick who wrote (9762)	6/8/1998 1:46:00 PM
From: Barney	Respond to of 18691

>>>You ought to direct your response to those who have been screaming FRAUD without providing the necessary proof.<<< Nick, I for one am very tired of you and your caustic, acrimonious postings. Why don't you go find another playground to play in. FWIW, I'm going to place you on ignore from now on. Good Trading, Barney

To: Nick who wrote (9762)	6/9/1998 8:35:00 AM
From: Mama Bear	Read Replies (2) \| Respond to of 18691

Nick, I do want to extend my gratitude for spurring my interest in shorting CCSI yesterday. I doubt that I would have looked into it without your posts. I haven't had occasion to get into an Asensio pick before he actually announced it in the past (see press release below). Barb ---------------------------------------------------------------------- Asensio & Company, Inc.: Chromatics Has No Material Sales or Earnings Potential NEW YORK, June 9 /PRNewswire/ -- The following was issued today by Asensio & Company, Inc.: Asensio & Company, Inc. issued an institutional research report and initiated coverage of Chromatics Color Sciences International, Inc.'s (OTC Bulletin Board: CCSI - news) common stock with a Strong Sell and Short Sell recommendation. Investors are buying shares of Chromatics Color Sciences International, Inc. believing that the company has developed a proprietary medical instrument, the Colormate III, which offers certain unique advantages in a market it estimates to be between $330 and $510 million. These product and market size claims are completely false and untrue. The Colormate III is a simple, common non-invasive bilirubinometer. Non-invasive bilirubinometers are inexpensive colorimeters adapted to generate estimates of bilirubin blood levels. They have been in use since the 1950's. In fact, the Colormate III itself is over 10 years old, was FDA approved for marketing almost a year ago and has yet to register a single sale. Frost & Sullivan estimates the entire world market for bilirubinometers to be less than $2.5 million per year. Chromatics' widely published claim that this smallest of segments of the clinical laboratory instrument market is over 100 to 200 times its actual size is absurd. Chromatics lacks any reasonable or factual support for any of its product and market claims. Any information to the contrary is necessarily false and misleading. We believe that Chromatics has purposely disseminated such false and misleading information in order to defraud investors. We further believe Chromatics' stock rise is based on the belief that the Colormate III has the potential to generate significant earnings. There is no truth to this belief. As a result, we believe the shares will soon trade below $1.00 per share. Chromatics has approximately 19.4 million fully diluted shares outstanding including all outstanding preferred shares, options and warrants. At yesterday's closing bid price, Chromatics had a fully diluted market value of approximately $170 million. In the latest twelve-month period Chromatics had $9,700 and $6.1 million in operating revenues and losses, respectively. Chromatics' only source of funds is a system of below market private stock sales followed by registrations that allow the private stock to be resold publicly, and fraudulent stock promotions. After its Investors Associates, Inc. underwriting, Chromatics had 4.1 million shares of common stock outstanding. Investors Associates and its principals were expelled from the securities business and charged with securities fraud. Today, Chromatics has 14.8 million shares outstanding. Using its method of private stock sales and fraudulent promotions, Chromatics has sold an additional 10.7 million shares of its stock at an average private selling price of $2.00 per share without ever selling a single additional share through an underwriting. These shares were then resold at a profit to public investors. Asensio & Company is a New York based institutional investment bank specializing in corporate valuations and equity research. Asensio & Company also specializes in investigating fraudulent stock promotions and publishing research on grossly overvalued companies. Asensio & Company's published research reports, including a copy of our report on Chromatics Color Sciences International, Inc. and a complete record of our previous Strong Sell reports, are available on Asensio & Company's Internet home page located at www.asensio.com. Copyright 1988 by Asensio & Company, Inc. All rights reserved. This report should not be construed as an offer to sell or solicitation of an offer to buy any securities. Opinions expressed are subject to change without notice. This report has been prepared from original sources and data which we believe to be reliable but accuracy is not guaranteed. This research report was prepared by Asensio & Company, Inc., whose stockholders, officers and employees may from time to time acquire, hold or sell a position in the securities mentioned herein. Asensio & Company, Inc., may act as pricipal for its own account or may sell or buy to or from its customers the securities described herein. Asensio & Company, Inc. from time to time perform investment banking or other services for, or solicit investment banking or other services from, any company mentioned in this report or its affiliates. SOURCE: Asensio & Company, Inc.